2023 Partners
Program Partner:
Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems to empower confident decision-making at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal & metabolic diseases and oncology.
Program Partner:
SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver, and metabolic diseases.
Hosting Partner:
Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: NASH, dyslipidemia, inflammation, fibrosis, diabetic nephropathy, neuropathy, HFpEF and atherosclerosis. For 20 years, Physiogenex has been evaluating the efficacy of its clients' drugs using gold-standard and radiotracer-based experiments in our validated preclinical models. With a 97.5% satisfaction rate last year, our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners.